Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kyntra BioLTS:0IL8 -1.24%50 Cash Ratio is 2.53 as of Jun. 2026, which is 20% below its 10-year median of 3.18. GuruFocus rates LTS:0IL8 with a GF Score™ of 50/100 and a GF Value™ of $4.72 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,385 Biotechnology companies, Kyntra Bio ranks worse than 54.01% on this metric.
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Kyntra Bio Cash Ratio Related Terms
Kyntra Bio Cash Ratio Historical Data
* Premium members only.
The historical data trend for Kyntra Bio's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0IL8 vs ACTU, PLRZ, IGC: Cash Ratio Comparison
For the Biotechnology subindustry, Kyntra Bio's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kyntra Bio Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kyntra Bio's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Kyntra Bio's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kyntra Bio (LTS:0IL8) has a Cash Ratio of 2.53 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Kyntra Bio and its competitors. This is 20% below median its historical median of 3.18. Over the past decade, Kyntra Bio's Cash Ratio has ranged from 0.15 to 10.66. According to the industry distribution chart, Kyntra Bio ranks #748 out of 1385 companies in the Biotechnology industry, placing it in the top 54%.
Is Kyntra Bio's Cash Ratio too high?
Kyntra Bio's current Cash Ratio of 2.53 is 20% below median its 10-year median of 3.18. Over the past 10 years, this metric has ranged from a low of 0.15 to a high of 10.66. The Biotechnology industry median Cash Ratio is 2.96. Kyntra Bio's value of 2.53 is 14.5% below this industry median. Based on the distribution chart, Kyntra Bio ranks #748 out of 1385 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Kyntra Bio has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kyntra Bio's Cash Ratio compare to ACTU and PLRZ?
According to the Biotechnology industry distribution chart, Kyntra Bio ranks #748 out of 1385 companies for Cash Ratio. This places Kyntra Bio in the lower half of its industry. The industry median Cash Ratio is 2.96. Kyntra Bio's value of 2.53 is 14.5% below this benchmark. Historically, Kyntra Bio's own Cash Ratio has ranged from 0.15 to 10.66 over the past decade. While the company's 10-year median is 3.18 vs. the industry median of 2.96, Kyntra Bio has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.96, based on 1,385 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kyntra Bio's current Cash Ratio of 2.53 is 14.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Kyntra Bio and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kyntra Bio's current Cash Ratio is 2.53, which is 20% below median its own 10-year median of 3.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyntra Bio stock overvalued right now?
Based on GuruFocus' analysis, Kyntra Bio (LTS:0IL8) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.72, compared to a current price of $7.07 — trading 49.8% above its estimated fair value. The current Cash Ratio is 2.53, which is 20% below median its 10-year median of 3.18 and 14.5% below the Biotechnology industry median of 2.96. Kyntra Bio's overall GF Score™ is 50/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Kyntra Bio (LTS:0IL8), the current Cash Ratio is 2.53 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kyntra Bio (LTS:0IL8) Overvalued in 2026?
Based on GuruFocus' analysis, Kyntra Bio stock appears to be overvalued.
The current stock price of $7.07 is trading 49.8% above its estimated GF Value™ of $4.72.
GuruFocus considers Kyntra Bio to be Significantly Overvalued.
Key valuation signals for LTS:0IL8:
Cash Ratio: 2.53 (20% below median its 10-year median of 3.18)
GF Value™: $4.72 vs. price of $7.07 (49.8% above fair value)
Industry Position: 14.5% below the Biotechnology median (#748 of 1385)
No single metric tells the full story. See the LTS:0IL8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
50GF Score
Get the complete analysis for LTS:0IL8
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0IL8 has been successfully added to your 
